Indivior (OTCMKTS:INVVY) & Amneal Pharmaceuticals (NASDAQ:AMRX) Critical Analysis

Indivior (OTCMKTS:INVVY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Indivior and Amneal Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	1	0	3.00
Amneal Pharmaceuticals	1	0	9	0	2.80

Indivior presently has a consensus target price of $50.00, suggesting a potential upside of 128.88%. Amneal Pharmaceuticals has a consensus target price of $21.25, suggesting a potential downside of 0.89%. Given Indivior’s stronger consensus rating and higher probable upside, analysts clearly believe Indivior is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Indivior and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Amneal Pharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

0.1% of Indivior shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Indivior and Amneal Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Amneal Pharmaceuticals	N/A	N/A	N/A	$0.49	43.76

Indivior has higher revenue and earnings than Amneal Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Indivior beats Amneal Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.